JP2021535733A - Ｉｌ−１１抗体 - Google Patents

Ｉｌ−１１抗体 Download PDF

Info

Publication number
JP2021535733A
JP2021535733A JP2020568955A JP2020568955A JP2021535733A JP 2021535733 A JP2021535733 A JP 2021535733A JP 2020568955 A JP2020568955 A JP 2020568955A JP 2020568955 A JP2020568955 A JP 2020568955A JP 2021535733 A JP2021535733 A JP 2021535733A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antigen
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020568955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535733A5 (https=
JPWO2019238882A5 (https=
Inventor
クック，スチュアート・アレクサンダー
シェーファー，セバスチャン
Original Assignee
シンガポール ヘルス サーヴィシーズ プライベート リミテッド
ナショナル ユニヴァーシティー オブ シンガポール
ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンガポール ヘルス サーヴィシーズ プライベート リミテッド, ナショナル ユニヴァーシティー オブ シンガポール, ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー filed Critical シンガポール ヘルス サーヴィシーズ プライベート リミテッド
Publication of JP2021535733A publication Critical patent/JP2021535733A/ja
Publication of JP2021535733A5 publication Critical patent/JP2021535733A5/ja
Publication of JPWO2019238882A5 publication Critical patent/JPWO2019238882A5/ja
Priority to JP2024076402A priority Critical patent/JP2024105466A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
JP2020568955A 2018-06-13 2019-06-13 Ｉｌ−１１抗体 Pending JP2021535733A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076402A JP2024105466A (ja) 2018-06-13 2024-05-09 Ｉｌ－１１抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1809699.0A GB201809699D0 (en) 2018-06-13 2018-06-13 IL-11 antibodies
GB1809699.0 2018-06-13
PCT/EP2019/065598 WO2019238882A1 (en) 2018-06-13 2019-06-13 Il-11 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076402A Division JP2024105466A (ja) 2018-06-13 2024-05-09 Ｉｌ－１１抗体

Publications (3)

Publication Number Publication Date
JP2021535733A true JP2021535733A (ja) 2021-12-23
JP2021535733A5 JP2021535733A5 (https=) 2022-06-20
JPWO2019238882A5 JPWO2019238882A5 (https=) 2022-06-20

Family

ID=63042160

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020568955A Pending JP2021535733A (ja) 2018-06-13 2019-06-13 Ｉｌ−１１抗体
JP2024076402A Pending JP2024105466A (ja) 2018-06-13 2024-05-09 Ｉｌ－１１抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076402A Pending JP2024105466A (ja) 2018-06-13 2024-05-09 Ｉｌ－１１抗体

Country Status (25)

Country Link
US (4) US11084874B2 (https=)
EP (1) EP3807314A1 (https=)
JP (2) JP2021535733A (https=)
KR (1) KR20210031690A (https=)
CN (1) CN113056481A (https=)
AU (2) AU2019286795B2 (https=)
BR (1) BR112020025443A2 (https=)
CA (1) CA3102483A1 (https=)
CL (1) CL2020003223A1 (https=)
CO (1) CO2020015383A2 (https=)
CR (1) CR20210009A (https=)
DO (2) DOP2020000245A (https=)
EA (1) EA202092668A1 (https=)
EC (1) ECSP21000695A (https=)
GB (1) GB201809699D0 (https=)
IL (1) IL279356A (https=)
JO (1) JOP20200309A1 (https=)
MA (1) MA52884A (https=)
MX (1) MX2020013583A (https=)
PE (1) PE20211498A1 (https=)
PH (1) PH12020552232A1 (https=)
SA (1) SA520420801B1 (https=)
SG (1) SG11202011782XA (https=)
TW (1) TW202003560A (https=)
WO (1) WO2019238882A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
AU2017378111A1 (en) 2016-12-16 2019-06-13 National University Of Singapore IL-11 antibodies
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
TWI858005B (zh) * 2019-01-21 2024-10-11 新加坡商新加坡保健服務私人有限公司 肝毒性之治療
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
CN114364693A (zh) 2019-05-03 2022-04-15 新加坡保健服务私人有限公司 代谢性疾病的治疗和预防
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
CN116601169A (zh) * 2020-07-20 2023-08-15 生物综合治疗有限公司 针对马尔堡病毒的广泛中和结合分子
WO2022033538A1 (zh) * 2020-08-13 2022-02-17 广东东阳光药业有限公司 Il-11的抗体及其应用
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
MX2023009946A (es) 2021-02-26 2023-09-04 Bayer Ag Inhibidores de il-11 o il-11ra para uso en el tratamiento de sangrado uterino anormal.
US20250092126A1 (en) 2021-07-26 2025-03-20 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
JP2024532709A (ja) * 2021-08-12 2024-09-10 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｉｌ－１１ヒト化抗体及びその用途
KR20240067079A (ko) 2021-08-30 2024-05-16 라센 테라퓨틱스 1, 인코포레이티드 항-IL-11Rα 항체
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
CN116891528A (zh) 2022-01-29 2023-10-17 迈威(上海)生物科技股份有限公司 一种抗白介素-11的抗体及其应用
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
CN118307670A (zh) 2023-01-06 2024-07-09 广东东阳光药业股份有限公司 抗il-11细胞因子人源化抗体
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
CN120518761B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2025026206A1 (zh) * 2023-07-28 2025-02-06 迈威(上海)生物科技股份有限公司 抗白介素-11抗体在制备肿瘤治疗药物中的应用
WO2025108343A1 (zh) * 2023-11-22 2025-05-30 上海华奥泰生物药业股份有限公司 靶向il-11的抗原结合蛋白
WO2025146029A1 (zh) * 2024-01-02 2025-07-10 上海华奥泰生物药业股份有限公司 靶向il-11和tslp的多特异性分子
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
WO2026001793A1 (zh) * 2024-06-27 2026-01-02 上海华奥泰生物药业股份有限公司 靶向il-11的抗原结合蛋白及其用途
CN119119262B (zh) * 2024-08-02 2025-05-02 杭州曼迪生物科技有限公司 一种干细胞冻干粉及其在制备药物或者化妆品中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183544A1 (en) * 2008-10-14 2010-07-22 Csl Limited Method of treatment
WO2017103108A1 (en) * 2015-12-16 2017-06-22 Singapore Health Services Pte Ltd Treatment of fibrosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335336B (https=) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
RU2016125115A (ru) * 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
AU2017378111A1 (en) 2016-12-16 2019-06-13 National University Of Singapore IL-11 antibodies
RU2016151730A (ru) * 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183544A1 (en) * 2008-10-14 2010-07-22 Csl Limited Method of treatment
WO2017103108A1 (en) * 2015-12-16 2017-06-22 Singapore Health Services Pte Ltd Treatment of fibrosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. CHENG, ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 338, JPN6023016104, 2005, pages 1654 - 1660, ISSN: 0005045215 *
S. SCHAEFER, ET AL., EUROPEAN HEART JOURNAL, vol. Vol.38, Supplement 1, JPN6023016103, 2017, pages 1412 - 2885, ISSN: 0005045214 *

Also Published As

Publication number Publication date
US20240270837A1 (en) 2024-08-15
CN113056481A (zh) 2021-06-29
US20210230266A1 (en) 2021-07-29
MA52884A (fr) 2021-04-21
JP2024105466A (ja) 2024-08-06
ECSP21000695A (es) 2021-03-31
KR20210031690A (ko) 2021-03-22
SA520420801B1 (ar) 2023-12-07
CO2020015383A2 (es) 2021-04-19
CL2020003223A1 (es) 2021-07-30
PE20211498A1 (es) 2021-08-11
EP3807314A1 (en) 2021-04-21
IL279356A (en) 2021-01-31
AU2019286795B2 (en) 2026-03-12
AU2026201704A1 (en) 2026-03-26
GB201809699D0 (en) 2018-08-01
AU2019286795A1 (en) 2021-01-28
BR112020025443A2 (pt) 2021-03-16
WO2019238882A1 (en) 2019-12-19
PH12020552232A1 (en) 2021-06-28
CA3102483A1 (en) 2019-12-19
TW202003560A (zh) 2020-01-16
US20240190953A1 (en) 2024-06-13
DOP2020000245A (es) 2021-10-31
SG11202011782XA (en) 2020-12-30
US11084874B2 (en) 2021-08-10
EA202092668A1 (ru) 2021-05-18
DOP2024000220A (es) 2025-02-28
US20200031918A1 (en) 2020-01-30
CR20210009A (es) 2021-06-21
JOP20200309A1 (ar) 2020-11-30
MX2020013583A (es) 2021-04-13

Similar Documents

Publication Publication Date Title
US20240190953A1 (en) Il-11 antibodies
JP7437325B2 (ja) Ｉｌ－１１ｒａ抗体
JP7181870B2 (ja) Ｉｌ－１１抗体
US20240002515A1 (en) Methods and antibodies for modulation of immunoresponse
JP7175271B2 (ja) ＩＬ－１１Ｒα抗体
JP2021510535A (ja) Ｈｅｒ３抗原結合性分子
JP2021511818A (ja) Ｖｉｓｔａ抗原結合性分子
TW201833135A (zh) 抗－ＴＧＦ－β抗體及其用途
US20240400698A1 (en) Anti-chemokin like receptor 1 antibodies and their therapeutic applications
EA048010B1 (ru) Антитела к ил-11
CA2980495C (en) Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20210721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210721

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220609

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231024

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240509

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240517

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240802

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250110